✦ LIBER ✦

2013 ANTIVIRAL ACTIVITY, PHARMACOKINETICS AND SAFETY OF IDX184 IN COMBINATION WITH PEGYLATED INTERFERON (PEGIFN) AND RIBAVIRIN (RBV) IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED SUBJECTS

✍ Scribed by Lalezari, J.; Poordad, F.; Mehra, P.; Nguyen, T.; Dejesus, E.; Godofsky, E.; Patrick, G. Dubuc; Chen, J.; Pietropaolo, K.; Zhou, X.-J.; Sullivan-Bólyai, J.Z.; Mayers, D.

Book ID: 122501115
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 54 KB
Volume: 52
Category: Article
ISSN: 0168-8278
DOI: 10.1016/S0168-8278(10)61204-4

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1210 ABT-267 COMBINED WITH PEGYLATED INT

1210 ABT-267 COMBINED WITH PEGYLATED INTERFERON ALPHA-2A/RIBAVIRIN IN GENOTYPE 1 (GT1) HCV-INFECTED TREATMENT-NAIVE SUBJECTS: 12 WEEK ANTIVIRAL AND SAFETY ANALYSIS

✍ Sullivan, G.J.; Rodriques-Torres, M.; Lawitz, E.; Poordad, F.; Kapoor, M.; Campb 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 117 KB

2009 SAFETY AND ANTIVIRAL ACTIVITY OF AN

2009 SAFETY AND ANTIVIRAL ACTIVITY OF ANA598 IN COMBINATION WITH PEGYLATED INTERFERON α2A PLUS RIBAVIRIN IN TREATMENT-NAIVE GENOTYPE-1 CHRONIC HCV PATIENTS

✍ Lawitz, E.; Rodriquez-Torres, M.; Rustgi, V.K.; Hassanein, T.; Rahimy, M.H.; Cro 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 51 KB

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN

1052 ANTIVIRAL ACTIVITY OF FILIBUVIR IN COMBINATION WITH PEGYLATED INTERFERON ALFA-2A AND RIBAVIRIN FOR 28 DAYS IN TREATMENT NAIVE PATIENTS CHRONICALLY INFECTED WITH HCV GENOTYPE 1

✍ Jacobson, I.; Pockros, P.; Lalezari, J.; Lawitz, E.; Rodriguez-Torres, M.; DeJes 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 70 KB

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY

1190 SILEN-C2: EARLY ANTIVIRAL ACTIVITY AND SAFETY OF BI 201335 COMBINED WITH PEGINTERFERON ALFA-2A AND RIBAVIRIN (PEGIFN/RBV) IN CHRONIC HCV GENOTYPE-1 PATIENTS WITH NON-RESPONSE TO PEGIFN/RBV

✍ Sulkowski, M.; Bourliere, M.; Bronowicki, J.-P.; Streinu-Cercel, A.; Preotescu, 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 68 KB

1208 BIT225, AN HCV-P7 INHIBITOR, WITH E

1208 BIT225, AN HCV-P7 INHIBITOR, WITH ENHANCED ANTI-HCV ACTIVITY IN COMBINATION WITH PEGYLATED INTERFERONalfa- 2b AND RIBAVIRIN IN HCV GENOTYPE-1 TREATMENT NAÏVE SUBJECTS: PHARMACOKINETIC AND RESISTANCE STUDIES

✍ Ewart, G.; Luscombe, C.; Huang, Z.; Miller, M.; Wilkinson, J.; Murphy, R.; Tanwa 📂 Article 📅 2013 🏛 Elsevier Science 🌐 English ⚖ 53 KB

1412 INTERFERON-FREE TREATMENT WITH A CO

1412 INTERFERON-FREE TREATMENT WITH A COMBINATION OF MERICITABINE AND DANOPREVIR/R WITH OR WITHOUT RIBAVIRIN IN TREATMENT-NAIVE HCV GENOTYPE 1-INFECTED PATIENTS

✍ Gane, E.J.; Pockros, P.; Zeuzem, S.; Marcellin, P.; Shikhman, A.; Bernaards, C.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 83 KB